Usefulness of fibrinogenolytic and procoagulant markers during thrombolytic therapy in predicting clinical outcomes in acute myocardial infarction. TIMI-5 Investigators. Thrombolysis in Myocardial Infarction.

[1]  G. Ewald,et al.  Plasmin-mediated activation of contact system in response to pharmacological thrombolysis. , 1995, Circulation.

[2]  C. Cannon,et al.  A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. , 1994, Journal of the American College of Cardiology.

[3]  Gusto Angiographic Investigators.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[4]  U. Tebbe,et al.  Impact of early perfusion status of the infarct-related artery on short-term mortality after thrombolysis for acute myocardial infarction: retrospective analysis of four German multicenter studies. , 1993, Journal of the American College of Cardiology.

[5]  M. J. Hursting,et al.  Monoclonal antibodies specific for prothrombin fragment 1.2 and their use in a quantitative enzyme-linked immunosorbent assay. , 1993, Clinical chemistry.

[6]  A. Stead,et al.  Effects of age, race, sex, and smoking on prothrombin fragment 1.2 in a healthy population. , 1993, Clinical Chemistry.

[7]  D. Collen,et al.  Plasma Fibrinopeptide A Levels in Patients With Acute Myocardial Infarction Treated With Alteplase: Correlation With Concomitant Heparin, Coronary Artery Patency, and Recurrent Ischemia , 1992, Circulation.

[8]  P. Declerck,et al.  Plasma levels of plasminogen activator inhibitor type 1, beta-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase. , 1991, Blood.

[9]  K. Mann,et al.  Fibrin fragment D-dimer and fibrinogen B beta peptides in plasma as markers of clot lysis during thrombolytic therapy in acute myocardial infarction. , 1990, Blood.

[10]  A. Haeberli,et al.  Monitoring of fibrin generation during thrombolytic therapy of acute myocardial infarction with recombinant tissue-type plasminogen activator. , 1989, Circulation.

[11]  S. Butman,et al.  Fibrin Metabolism in Patients with Acute Myocardial Infarction During and After Treatment with Tissue-Type Plasminogen Activator , 1988, Thrombosis and Haemostasis.

[12]  K. Friedman,et al.  Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. , 1988, Blood.

[13]  H. Pelzer,et al.  Determination of Human Thrombin-Antithrombin III Complex in Plasma with an Enzyme-Linked Immunosorbent Assay , 1988, Thrombosis and Haemostasis.

[14]  A. Jaffe,et al.  Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. , 1987, Journal of the American College of Cardiology.

[15]  A. Jaffe,et al.  Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis. , 1986, Journal of the American College of Cardiology.

[16]  A. Jaffe,et al.  Fibrinopeptide A: a marker of acute coronary thrombosis. , 1985, Circulation.

[17]  B. Kudryk,et al.  A monoclonal antibody with ability to distinguish between NH2-terminal fragments derived from fibrinogen and fibrin. , 1983, Molecular immunology.

[18]  S. Frebelius,et al.  Rapid radioimmunoassay of human fibrinopeptide A - removal of cross-reacting fibrinogen with bentonite. , 1980, Thrombosis research.

[19]  S. Niewiarowski,et al.  Significance of the intact polypeptide chains of human fibrinogen in ADP-induced platelet aggregation , 1977 .

[20]  V. Vinciguerra,et al.  Ultrastructural cytochemical analysis of blastic transformation of chronic myelocytic leukemia. , 1977, Blood.